Labcorp Holdings Inc. $LH Shares Bought by Blair William & Co. IL

Blair William & Co. IL raised its holdings in Labcorp Holdings Inc. (NYSE:LH) by 190.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 11,697 shares of the medical research company’s stock after purchasing an additional 7,675 shares during the period. Blair William & Co. IL’s holdings in Labcorp were worth $3,358,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Independent Advisor Alliance boosted its holdings in Labcorp by 166.6% in the 3rd quarter. Independent Advisor Alliance now owns 12,111 shares of the medical research company’s stock worth $3,477,000 after buying an additional 7,568 shares during the last quarter. New York State Common Retirement Fund raised its holdings in shares of Labcorp by 12.0% during the third quarter. New York State Common Retirement Fund now owns 44,795 shares of the medical research company’s stock valued at $12,859,000 after acquiring an additional 4,800 shares during the last quarter. Dakota Wealth Management lifted its position in shares of Labcorp by 98.6% in the third quarter. Dakota Wealth Management now owns 10,303 shares of the medical research company’s stock valued at $2,958,000 after acquiring an additional 5,116 shares in the last quarter. Lazard Asset Management LLC lifted its position in shares of Labcorp by 224.1% in the second quarter. Lazard Asset Management LLC now owns 989,433 shares of the medical research company’s stock valued at $259,734,000 after acquiring an additional 684,153 shares in the last quarter. Finally, Franklin Resources Inc. boosted its stake in shares of Labcorp by 3.1% in the second quarter. Franklin Resources Inc. now owns 34,331 shares of the medical research company’s stock worth $9,012,000 after acquiring an additional 1,043 shares during the last quarter. 95.94% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Labcorp

In related news, EVP Der Vaart Sandra D. Van sold 548 shares of the stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $284.91, for a total transaction of $156,130.68. Following the transaction, the executive vice president owned 2,579 shares of the company’s stock, valued at approximately $734,782.89. This represents a 17.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Jonathan C. Meltzer sold 87 shares of the firm’s stock in a transaction dated Thursday, February 12th. The shares were sold at an average price of $290.42, for a total value of $25,266.54. Following the transaction, the executive vice president owned 2,782 shares of the company’s stock, valued at $807,948.44. This trade represents a 3.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 16,113 shares of company stock worth $4,547,450 in the last ninety days. 0.84% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages have issued reports on LH. Weiss Ratings raised shares of Labcorp from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, February 10th. Robert W. Baird raised their price target on shares of Labcorp from $313.00 to $326.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 18th. Wall Street Zen upgraded shares of Labcorp from a “hold” rating to a “buy” rating in a research report on Friday, January 23rd. Morgan Stanley reaffirmed an “overweight” rating on shares of Labcorp in a research note on Tuesday, February 17th. Finally, Piper Sandler increased their price objective on shares of Labcorp from $270.00 to $300.00 and gave the company a “neutral” rating in a report on Tuesday, February 24th. Nine analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $304.82.

Labcorp Price Performance

LH stock opened at $270.27 on Thursday. Labcorp Holdings Inc. has a 52-week low of $209.38 and a 52-week high of $293.72. The company has a quick ratio of 1.23, a current ratio of 1.42 and a debt-to-equity ratio of 0.60. The stock has a market cap of $22.27 billion, a price-to-earnings ratio of 25.84, a price-to-earnings-growth ratio of 1.83 and a beta of 1.01. The business has a fifty day moving average of $272.12 and a two-hundred day moving average of $270.12.

Labcorp (NYSE:LH) last issued its quarterly earnings data on Tuesday, February 17th. The medical research company reported $4.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.95 by $0.12. Labcorp had a net margin of 6.28% and a return on equity of 16.16%. The firm had revenue of $3.52 billion for the quarter, compared to analyst estimates of $3.56 billion. During the same period in the previous year, the firm earned $3.45 EPS. Labcorp’s revenue was up 5.6% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. As a group, research analysts anticipate that Labcorp Holdings Inc. will post 16.01 earnings per share for the current year.

Labcorp Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 12th. Investors of record on Friday, February 27th will be issued a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 1.1%. The ex-dividend date is Friday, February 27th. Labcorp’s dividend payout ratio (DPR) is 27.53%.

Labcorp Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.